Sue Hager

Chief Communications Officer, SVP Corporate Affairs & Citizenship, EQRx

About Sue

Sue Hager brings more than two decades of life sciences enterprise leadership and stakeholder communications expertise to her role at EQRx. Most previously, Sue served as Senior Vice President of Corporate Communications, Government Affairs and Advocacy for Foundation Medicine. In this role, Sue directed the stewardship of Foundation Medicine’s corporate brand, led strategic communications for internal and external stakeholders, and spearheaded advocacy efforts focused on accelerating patient access to genomic testing in oncology. During her tenure, Foundation Medicine became one of the most recognized brands in genomic testing for people with advanced cancer.

Prior to Foundation Medicine, Sue was Senior Vice President, Corporate Communications for Myriant Corporation, a renewable bio-based chemicals company, where she led strategic communications and investor relations, as well as policy and project finance efforts supporting funding and commercialization of “green” chemicals in the United States. Her efforts contributed to the building of the first at-scale, bio-based renewables chemicals manufacturing plant in the US prior to the company’s sale to PTT Global Chemical. Previously, Sue held senior communications leadership positions in life sciences organizations including Targanta Therapeutics, Coley Pharmaceutical Group and Bayer Healthcare, among others, where she led initiatives spanning corporate affairs, corporate and marketing communications, investor relations, advocacy and corporate development. Over her career, she has architected and directed marketing communications campaigns to support the successful launches of more than two dozen therapeutics, diagnostics and digital health products worldwide.

Sue holds an MBA and a B.S. degree in biology with honors from Northeastern University in Boston, MA. She serves on the Boston Friends of Pablove, a non-profit foundation dedicated to improving the lives of children with cancer through the art and science.

See all Board Members